Tech Company Financing Transactions
Ignyta Funding Round
City Hill Ventures, Colt Ventures and private investors participated in a $6 million Series B capital raise for Ignyta. This VC investment round was announced on 1/1/2013.
Transaction Overview
Company Name
Announced On
1/1/2013
Transaction Type
Venture Equity
Amount
$6,000,000
Round
Series B
Investors
City Hill Ventures (Jonathan Lim)
Proceeds Purpose
The company plans to use proceeds of its current round in 2013 to begin clinical studies to confirm its molecular based assay for diagnosing RA at its earliest, most-treatable stages.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
11095 Flintkote Avenue d
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
Ignyta is developing leading cancer treatments by developing selective tyrosine kinase inhibitors of the TrkA, TrkB, TrkC, ROS1 and ALK proteins.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jonathan Lim
Chief Financial Officer
Jacob Chacko
Chief Medical Officer
Adrian Senderowicz
Chief Operating Officer
Zachary Hornby
Chief Scientific Officer
Robert Wild
VP - General Counsel
Matt Onaitis
Browse more venture capital transactions:
Prev: 1/1/2013: The Fancy venture capital transaction
Next: 1/2/2013: NanoHorizons venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC transactions on this site come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs